Accession Therapeutics Limited
PrivateLast Round
Grant
Mar 24, 2026
Est. Valuation
$100.93M
Total Funding Raised
$44.23M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Accession Therapeutics Limited is a biopharmaceutical company developing a novel class of tumour-targeted immunotherapies through its proprietary TROCEPT platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Accession Therapeutics Limited Comparables
Compare Accession Therapeutics Limited with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| KaliVir Immunotherapeutics | 87% | |
| TILT Biotherapeutics | 87% | |
| Theolytics | 86% |
Accession Therapeutics Limited Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 24, 2026 | ||||
| VC Round | Mar 18, 2026 | ||||
| VC Round | Dec 4, 2025 | ||||
| VC Round | Apr 25, 2024 | ||||
| Series A | Nov 21, 2022 | ||||
Seed | Sep 20, 2021 |
Key People
Founding team and executive leadership
Accession Therapeutics Limited Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Birk Venture | Seed, Series A |
| Cancer Research UK | Series A |
| iGlobe Partners | VC Round, Series A |
| Primavera Venture Partners | Seed, VC Round, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 67% MoM.
- Mar 24, 2026
Received $9M in grant funding from the European Commission.
Accession Therapeutics Limited Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Accession Therapeutics Limited's valuation, stock price, and market status.
Is Accession Therapeutics Limited a public or private company?
Accession Therapeutics Limited is a private company.
What is the current stock price of Accession Therapeutics Limited?
Accession Therapeutics Limited is a private company with no public stock price. Caplight tracks Accession Therapeutics Limited's secondary market activity and provides MarketPrice™ estimates to Caplight users.
How much is Accession Therapeutics Limited worth (valuation)?
Accession Therapeutics Limited's valuation is estimated at $100.9M based on funding round data.
Can I buy Accession Therapeutics Limited stock?
Accession Therapeutics Limited shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Accession Therapeutics Limited's last funding round?
Accession Therapeutics Limited's most recent funding round was Grant on March 18, 2026.
Who are the main investors in Accession Therapeutics Limited?
Key investors in Accession Therapeutics Limited include iGlobe Partners, Primavera Venture Partners.
Will Accession Therapeutics Limited IPO soon?
No public IPO plans have been announced for Accession Therapeutics Limited.
How can I track Accession Therapeutics Limited secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Accession Therapeutics Limited's secondary market activity and sign up for updates.